Distinguished allergist-immunologist in USA

Distinguished allergist-immunologist in USA

Alkis Togias is an allergist-immunologist and works as Chief of the Asthma and Inflammation Section at the National Institute of Allergy and Infectious Diseases. Recently he was part of a large research that shows how immunotherapy can take up to three years to have long-term effects.

Alkis Togias received his medical degree from the National and Kapodistrian University of Athens in 1983. For the period 1982-1983, he was a trainee at the Division of Clinical Immunology at the John Hopkins University School of Medicine and from July 1983 until June 1985, he was appointed as a research fellow. In 1985, he was intern at The Osler Medical Service and in 1986 a junior assistant resident. In 1987, he became senior assistant resident and in July 1988, a clinical fellow. He completed his studies and education in June 1989.

The Greek immunologist started working as an instructor of Medicine at John Hopkins University in July 1989. He remained in that position until March 1991 and then he was appointed as an assistant professor of Medicine at the Division of Clinical Immunology and Pulmonary and Critical Care Medicine. In February 1996, he was promoted to associate professor of Medicine, a position he kept until September 2006.

In October 2006, Alkis Togias became Section Chief of Asthma and Airway Biology at the National Institute of Allergy and Infectious Diseases (NIAID). In February 2013, he was promoted to Branch Chief.

He is responsible of the management of the NIAID research portfolio in allergy, asthma and airway biology, which includes all clinical networks. He is the medical officer responsible for various NIAID-funded clinical trials and organizes all the workshops and publications sponsored by DAIT/NIAID in the fields of allergy, asthma and airway biology.

Recently, Alkis Togias was part of a research that proved that immunotherapy can fight the symptoms of the seasonal allergic rhinitis like nose bloating, sneezing and eye irritations with the help of a monthly injection or a daily pill but it can take up to three years to have long-term effects.  The results were published at the American medical journal JAMA (Journal of the American Medical Association).